Ultima Vez Modificado: 19 de febrero del 2006
Dear OncoLink "Ask The Experts,"
My father was recently diagnosed with synovial sarcoma in the lining of the lung. It was suggested that he undergo chemo therapy treatment with Doxil®. He's an older man with a heart condition, and based on what I read, I'm concerned about the cardiac ramifications.
Carolyn Vachani RN, MSN, AOCN, OncoLink's Nurse Educator, responds:
Doxil® is an anthracycline chemotherapy drug that is known to cause heart muscle damage. This damage can affect how well the heart pumps in some patients. The risk of heart damage applies to all chemotherapies of the anthracycline class. A patient should be screened with a MUGA scan or an ECHO (done by a cardiologist) before receiving Doxil® to obtain the patient's "ejection fraction" (EF). The EF is a measure of the baseline heart function that can later be affected by Doxil®. If the patient's EF is too low to begin with, then another drug should be used. Otherwise, the patient can receive Doxil® but should be monitored closely for any heart problems during treatment.Imprima English
Sep 18, 2014 - It may be possible to prevent cardiomyopathy caused by chemotherapy by obtaining cardiac progenitor cells before initiating treatment and using them for prevention or management of heart failure, according to the findings of a study in rats published online Dec. 28 in Circulation.
Sep 18, 2014
Jul 9, 2010
Sep 18, 2014